Dyne Therapeutics Inc
DYN
Market Cap$3.27B
Close$
$4.37
61.7% downside
Current Fair Value
61.7% downsideOvervalued by 61.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.27 Billion |
|---|---|
| Enterprise Value | $2.86 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-3.95 |
| Beta | 1.05 |
| Outstanding Shares | 92,507,815 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -11.7 |
|---|---|
| PEG | -19.08 |
| Price to Sales | - |
| Price to Book Ratio | 1.9 |
| Enterprise Value to Revenue | 754.91 |
| Enterprise Value to EBIT | -9.09 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Dyne Therapeutics Inc
47 employeesDyne Therapeutics, Inc. operates as a biotechnology company. The Company focuses on transforming the lives of people with serious diseases by developing muscle-targeted therapies. Dyne Therapeutics offers its services in the United States.